Safety of Nasal Influenza Immunisation in Children With Asthma

Asthma Clinical Trial

— SNIFFLE-4  

Official title:

Safety of Nasal Influenza Immunisation in Children With Asthma - The SNIFFLE-4 Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02866942
• Other study ID #: 16SM3348
• Secondary ID: 2016-002352-24
• Status: Completed
• Phase: Phase 4
• Start date: October 2016
• Est. completion date: March 2017

Study information

• Verified date: May 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. In the United Kingdom (UK), the vaccine has been demonstrated to be highly effective against influenza infection. Further, despite concerns that LAIV can cause wheezing in children under age 2 years, the previous SNIFFLE studies have demonstrated it to be safe in children over 2 years with mild-moderate asthma.

The objective of this multicentre study is to further assess the safety of intranasal LAIV in children with asthma and recurrent wheeze, including those with severe symptoms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 479
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• Aged 2 - 18 years old (inclusive)

• Physician diagnosis of asthma or recurrent wheezing (by the hospital specialist) AND (i) in children age 2-4 years: =2 exacerbations in the past year requiring oral steroids or observation in-hospital beyond 4 hours duration, OR (ii) in children = 5 years of age, receiving treatment equivalent to at least BTS/SIGN step 2 therapy.

• Written informed consent from parent/guardian (or the patient themselves from age 16 years), with assent from children aged 8 years and above wherever possible.

Exclusion Criteria:

1. Admission to Paediatric Intensive Care for invasive ventilation due to a respiratory illness in the preceding 2 years.

2. Contraindications to LAIV (notwithstanding allergy to egg protein), which include:

1. Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue)

2. Previous systemic allergic reaction to LAIV

3. Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the site PI to confirm patient suitability

4. Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids**.

**High-dose steroids is defined as a treatment course for at least one month, equivalent to a dose greater than 20mg prednisolone per day (any age), or for children under 20kg, a dose greater than 1mg/kg/day.

NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled/low-dose oral systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.

5. Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.

6. pregnancy

3. Contraindications to vaccination on that occasion, e.g. due to child being acutely unwell:

1. Febrile =38.0 degrees C in last 72 hours

2. *Acute wheeze in last 72 hours requiring treatment beyond that normally prescribed for regular use by the child's treating healthcare professional

3. *Recent admission to hospital in last 2 weeks for acute asthma

4. *Current oral steroid for asthma exacerbation or course completed within last 2 weeks

5. Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

• Items 3b-3d are relative contra-indications: Many children with "difficult-to-control" symptoms may meet fail to meet these criteria on a routine basis. Where these are present, the study centre PIs are able to authorise participation on a case-by-case basis, after assessing the child and their lung function at the time of enrolment.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Administration of Live attenuated influenza vaccine (LAIV)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	Public Health England

References & Publications (2)

Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol. 2015 Aug;136(2):376-81. doi: 10.1016/j.jaci.2014.12.1925. Epub 2015 Feb 13. — View Citation

Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE-2 Study Investigators. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. 2015 Dec 8;351:h6291. doi: 10.1136/bmj.h6291. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Asthma Symptoms and Control Pre and 4 Weeks Post LAIV, as Assessed by Validated Questionnaire	The validated questionnaire to be used will depend on the age of the enrolled child: Age 2-4 years: TRACK questionnaire; Age 5-11 years: Children's Asthma Control Test (C-ACT) score; Age 12+ years: Asthma Control Test (ACT) score; The change in score (using the appropriate questionnaire for age) between pre- and 4 weeks post LAIV will be used to assess the primary outcome across all participants. a change in (c-)ACT of at least 3 points, or 10 points for TRACK will be determined a significant change.; For TRACK, the minimum and maximum score possible is 0 and 100 respectively, the higher the score, the better is symptom control.; For c-ACT, the minimum and maximum score possible is 0 and 27 respectively, the higher the score, the better controlled are asthma symptoms.; For ACT, the minimum and maximum score possible is 5 and 25 respectively, the higher the score, the better controlled are asthma symptoms.	4 weeks post LAIV
Secondary	Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs) in Children Receiving LAIV	Incidence of a 'significant exacerbation' in asthma, defined as: i. At least 3 day course of oral steroids following an unscheduled contact with a healthcare professional; OR ii. Unscheduled visit to an Emergency department or admission to hospital for treatment of asthma symptoms, requiring systemic corticosteroids	Up to 4 weeks post LAIV administration